What the Medicare GLP-1 Bridge Means for Agents in 2026

CMS announced the Medicare GLP-1 Bridge in December 2025. It is a temporary program that runs from July 1 to December 31, 2026. It covers two specific GLP-1 weight loss drugs at a flat $50 per month copay.

This is a first. Medicare has never directly covered GLP-1 drugs for weight loss before 2026. Previously, Medicare only covered drugs like Ozempic and Mounjaro when prescribed for type 2 diabetes through Part D.

Which GLP-1 Drugs Are Covered

The Bridge covers three products for weight loss: Wegovy (all formulations), Foundayo (all formulations), and the Zepbound KwikPen. That is it.

Ozempic and Mounjaro are NOT covered for weight loss through the Bridge. They remain covered through Part D only when prescribed for type 2 diabetes. A client on Ozempic for weight management — not diabetes — cannot assume their drug transfers into Medicare smoothly.

Who Qualifies for the Bridge

To access the Medicare GLP-1 Bridge, a beneficiary must be enrolled in a Medicare Part D plan (either a standalone PDP or an MA-PD plan) for calendar year 2026. They must also have a BMI of 35 or higher, or a BMI of 27 or higher with additional clinical criteria.

If they are not enrolled in Part D, they cannot access Bridge coverage — even if they qualify on BMI. That is a plan enrollment detail that only an agent can walk them through before they turn 65.

The Coverage Detail That Will Confuse Every GLP-1 Patient Turning 65

The Medicare GLP-1 situation is genuinely confusing. Most patients currently on GLP-1 drugs have no idea which of their medications Medicare will cover, under what conditions, or what changes when they age in.

Ozempic vs. Wegovy — The Drug Name That Changes Everything

Semaglutide is the active ingredient in both Ozempic and Wegovy. Same molecule. Different brand names, different FDA approvals, and very different Medicare coverage rules.

Ozempic is FDA-approved for type 2 diabetes — covered by Part D for diabetes patients. Wegovy is FDA-approved for weight loss — covered by the GLP-1 Bridge starting July 2026. A client currently on Ozempic for weight management who turns 65 may need to switch to Wegovy to access Bridge coverage.

The Bridge Ends December 2026 — Then What?

The GLP-1 Bridge is temporary. It runs through December 31, 2026. Starting January 2027, ongoing weight loss coverage shifts to the BALANCE Model — a voluntary CMS program that individual Part D plans must choose to participate in.

If a client wants to stay on GLP-1 coverage after December 2026, they will likely need to be enrolled in a Part D plan that opts into the BALANCE Model. That means another plan selection decision during AEP 2026.

What GLP-1 Patients Turning 65 Mean for Your Medicare Pipeline

9% of adults 65 and older are currently on GLP-1 drugs. Among adults aged 50-64 — your primary T-65 prospect pool — the number is 22%. That is roughly 1 in 5 people in your target market.

10,000 people turn 65 every day. A meaningful share of them are on GLP-1 drugs and actively wondering how their prescription fits into Medicare.

The Plan Selection Pressure Point

BALANCE Model participation in 2027 will be plan-specific. Not every Part D plan will opt in. An agent who can advise a T-65 prospect on which plans are expected to participate — and why that matters for their GLP-1 coverage continuity — brings specific, hard-to-find value to the enrollment conversation.

Using GLP-1 Coverage as a T-65 Outreach Hook

A simple outreach hook — "Are you on Ozempic, Wegovy, or Zepbound and approaching 65? Medicare's new GLP-1 coverage rules are more nuanced than most agents will tell you. Here is what to know before you enroll" — will get attention from the right prospects right now.

For more on reaching T-65 prospects before the competition does, read What Are T-65 Leads and Why Agents Target Them First.

The Bottom Line for GLP-1 Medicare Agents in 2026

The Medicare GLP-1 Bridge launches July 2026. It is temporary, it has plan enrollment requirements, and it is followed by a voluntary model that individual Part D plans must choose to join. The agents who understand this will have a genuine, defensible advantage during AEP 2026.

22% of your T-65 prospect pool is on a GLP-1 drug right now. Most of them have no idea their plan selection matters for whether they keep their medication after December 2026. They need an agent who knows this. That can be you.

Not sure where your Medicare pipeline stands heading into AEP 2026?

Take the free 60-second assessment and get your personalized Medicare Lead Gen Roadmap. It shows you exactly where your current lead gen is breaking down and what to build first.

Get Your Free Medicare Lead Gen Roadmap

Or if you are ready to talk now, book a free 20-minute strategy call here. No pitch. Just a look at your market and what consistent T-65 appointments could look like for the rest of 2026.

Frequently Asked Questions

Q: Does Medicare cover GLP-1 drugs for weight loss in 2026? A: Yes, starting July 1, 2026. The Medicare GLP-1 Bridge covers Wegovy and Zepbound at a $50/month copay for eligible beneficiaries enrolled in a Medicare Part D plan. Ozempic and Mounjaro are only covered for type 2 diabetes under Part D, not for weight loss. The Bridge runs through December 31, 2026. Starting January 2027, ongoing GLP-1 weight loss coverage moves to the BALANCE Model, which is voluntary for Part D plans.

Q: What is the Medicare GLP-1 Bridge program? A: The Medicare GLP-1 Bridge is a temporary CMS demonstration running from July 1 to December 31, 2026. It covers Wegovy and Zepbound for weight loss at a $50/month copay for Medicare Part D enrollees with a BMI of 35 or higher, or 27 or higher with additional clinical criteria. Beneficiaries must be actively enrolled in a Part D plan to qualify.

Q: What happens to GLP-1 Medicare coverage after December 2026? A: After the GLP-1 Bridge ends December 31, 2026, coverage transitions to the BALANCE Model -- a voluntary CMS program that Part D plans must apply to join. Beneficiaries who want continued GLP-1 coverage may need to switch to a BALANCE-participating plan during AEP 2026.

Q: How does GLP-1 Medicare coverage affect T-65 enrollment conversations for agents? A: It creates a specific, urgent reason for the 22% of adults aged 50-64 currently on GLP-1 drugs to seek guidance from a knowledgeable Medicare agent. Coverage depends on drug name, diagnosis, and which Part D plans participate in the BALANCE Model starting 2027. Agents who can navigate these nuances will build trust faster with GLP-1-using T-65 prospects.